Miriam Bornhorst

Has grant

Ann and Robert H Lurie Children's Hospital of Chicago
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Children's National Hospital

Open Date: 2021-01-01

Close Date: 2021-12-31

Grant: Close

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Open Date: 2017-02-21

Close Date: 2022-02-21

Grant: Close

NFCN - Children's National Health System

Open Date: 2016-12-31

Close Date: 2019-12-31

Grant: Close

Parent to Parent: Family Training on ADHD

Open Date: 2013-06-15

Close Date: 2014-06-15

Grant: Close

Biomarkers for cognitive deficits associated with Neurofibromatosis type I

Open Date: 2012-12-31

Close Date: 2013-12-31

Articles (10)

Lay Summary Some children with brain tumors of the visual pathway do not respond to initial treatment and require additional treatment. This study looked at patients with brain tumors treated with a combination of two newer drugs: MEK inhibitors and bevacizumab. While this study identified that these drugs cause side effects, serious problems were rare, and the combination did not appear to cause more severe side effects. Importantly, none of the children with optic pathway tumors showed worsening vision while receiving treatment and some children had improvement or stopped losing vision, suggesting that this drug combination may be beneficial for certain patients.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

The contribution of rare pathogenic/likely pathogenic (P/LP) germline variants to pediatric central nervous system (CNS) tumor development remains understudied. Here, we characterized the prevalence and clinical significance of germline P/LP variants in cancer predisposition genes across 830 CNS tumor patients from the Pediatric Brain Tumor Atlas (PBTA). We identified germline P/LP variants in 23.3% (193/830) of patients and the majority (137/193) lacked clinical reporting of genetic tumor syndromes. Among P/LP carriers, 34.6% had putative somatic second hits or loss of function tumor alterations. Finally, we linked pathogenic germline variation with novel somatic events and patient survival to highlight the impact of germline variation on tumorigenesis and patient outcomes.

Year:

2025

Objectives Distinguishing between sporadic and germline/mosaic NF2-related schwannomatosis is important to ensure that patients have appropriate long-term care. With this report, we describe a unique case of a patient with 4 ipsilateral schwannomas and identify a combination of sequencing modalities that can accurately diagnose mosaic NF2-related schwannomatosis. Methods We present a 32-year-old woman with a familial history of vestibular schwannoma in her father and right-sided schwannomas involving the apical and basal turns of cochlea, lateral semicircular canal, and internal auditory canal (IAC). Genetic analysis of blood and frozen tissue from 2 tumors (intralabyrinthine and IAC tumors) was performed using next-generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA), and optical genome mapping (OGM). Results Germline testing for NF2, LZTR1, and SMARCB1 was negative. Tumor genetic testing revealed a shared NF2 pathogenic variant between the 2 tumors (“first hit”) but distinct “second hit” NF2 variants, including mosaic loss of chromosome 22 in the IAC tumor seen only with OGM, consistent with mosaic NF2-related schwannomatosis. Conclusions Multimodality sequencing, including NGS, MLPA, and OGM, was required to ensure appropriate diagnosis of mosaic NF2-related schwannomatosis in this patient. A similar approach can be used for other patients with multiple ipsilateral tumors and suspected tumor predisposition.

Year:

2024

Pediatric cancers are the leading cause of disease-related deaths in children and adolescents. Most of these tumors are difficult to treat and have poor overall survival. Concerns have also been raised about drug toxicity and long-term detrimental side effects of therapies. In this review, we discuss the advantages and unique attributes of zebrafish as pediatric cancer models and their importance in targeted drug discovery and toxicity assays. We have also placed a special focus on zebrafish models of pediatric brain cancers—the most common and difficult solid tumor to treat.

Year:

2024

Background Diffuse midline gliomas (DMG) are aggressive pediatric brain tumors that are diagnosed and monitored through MRI. We developed an automatic pipeline to segment subregions of DMG and select radiomic features that predict patient overall survival (OS). Methods We acquired diagnostic and post-radiation therapy (RT) multisequence MRI (T1, T1ce, T2, and T2 FLAIR) and manual segmentations from 2 centers: 53 from 1 center formed the internal cohort and 16 from the other center formed the external cohort. We pretrained a deep learning model on a public adult brain tumor data set (BraTS 2021), and finetuned it to automatically segment tumor core (TC) and whole tumor (WT) volumes. PyRadiomics and sequential feature selection were used for feature extraction and selection based on the segmented volumes. Two machine learning models were trained on our internal cohort to predict patient 12-month survival from diagnosis. One model used only data obtained at diagnosis prior to any therapy (baseline study) and the other used data at both diagnosis and post-RT (post-RT study). Results Overall survival prediction accuracy was 77% and 81% for the baseline study, and 85% and 78% for the post-RT study, for internal and external cohorts, respectively. Homogeneous WT intensity in baseline T2 FLAIR and larger post-RT TC/WT volume ratio indicate shorter OS. Conclusions Machine learning analysis of MRI radiomics has potential to accurately and noninvasively predict which pediatric patients with DMG will survive less than 12 months from the time of diagnosis to provide patient stratification and guide therapy.

Year:

2024

Background Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood central nervous system tumor. Diagnosis and monitoring of tumor response to therapy is based on magnetic resonance imaging (MRI). MRI-based analyses of tumor volume and appearance may aid in the prediction of patient overall survival (OS). Methods Contrast-enhanced T1- and FLAIR/T2-weighted MR images were retrospectively collected from children with classical DIPG diagnosed by imaging (n = 43 patients). MRI features were evaluated at diagnosis (n = 43 patients) and post-radiation (n = 40 patients) to determine OS outcome predictors. Features included 3D tumor volume (Twv), contrast-enhancing tumor core volume (Tc), Tc relative to Twv (TC/Twv), and Twv relative to whole brain volume. Support vector machine (SVM) learning was used to identify feature combinations that predicted OS outcome (defined as OS shorter or longer than 12 months from diagnosis). Results Features associated with poor OS outcome included the presence of contrast-enhancing tumor at diagnosis, >15% Tc/Twv post-radiation therapy (RT), and >20% ∆Tc/Twv post-RT. Consistently, SVM learning identified Tc/Twv at diagnosis (prediction accuracy of 74%) and ∆Tc/Twv at <2 months post-RT (accuracy = 75%) as primary features of poor survival. Conclusions This study demonstrates that tumor imaging features at diagnosis and within 4 months of RT can predict differential OS outcomes in DIPG. These findings provide a framework for incorporating tumor volume-based predictive analyses into the clinical setting, with the potential for treatment customization based on tumor risk characteristics and future applications of machine-learning-based analysis.

Year:

2024

Year:

2023

Collaborators (17)

Sharon Diskin

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Adam Resnick

Director

University of Pennsylvania

UNITED STATES
View details

Sebastian Waszak

Tenure Track Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Angela Waanders

Associate Professor

Ann and Robert H Lurie Children's Hospital of Chicago

UNITED STATES
View details

Debasish Roy

Staff Scientist

Children's National Health System

UNITED STATES
View details

Yong-Seok Lee

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Kara Maxwell

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Sara Pardej

Assistant Professor

Gonzaga University

UNITED STATES
View details

Jo Lynne Rokita

Director, Brain Tumor Institute Bioinformatics Core

Children's National Health System

UNITED STATES
View details

Tamar Green

Assistant Professor

Stanford University

UNITED STATES
View details

Brian Weiss

Division Chief

Riley Hospital for Children at Indiana University Health

UNITED STATES
View details

Marilyn Li

Associate Chair and Vice Chief of Division of Genomic Diagnoatics

Children's Hospital of Philadelphia

UNITED STATES
View details

Andrea T. Franson

-

UNITED STATES
View details

J. Elliott Robinson

Assistant Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Nicole Brossier

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Beth Stronach

University of Pittsburgh

UNITED STATES
View details

Darren Hargrave

University College London

UNITED KINGDOM
View details